Studies in febrile seizures

Publisher Website
Google Scholar
Abstract
The effects of various classes of pharmacologic agents on febrile seizures have been studied in animals and the inadequacy of conventional therapies has been confirmed. A method has been introduced for the laboratory evaluation of drugs with potential activity against febrile seizures. Pyrictal [pletharbital (1-phenyl-) 5,5-diethyl barbituric acid; BW No. 401)] a new therapy, has been developed for the prophylaxis of febrile seizures, In laboratory tests, it appears superior to drugs in current use. Compared with phenobarbital, it is equally potent as an anticonvulsant, and has minimal sedative effects and only 1/3 the toxicity; an antipyretic effect is obtained with nontoxic doses. In clinical trials, Pyrictal has had antipyretic activity in children with fever and acute infection, anticonvulsant effects in institutionalized epileptic patients, and antifebrile-anticonvulsant properties, which appear superior to those of phenobarbital, in children with fever and previous histories of febrile seizures. In epileptic patients, Pyrictal appears to be most effective in the treatment of major clonic, opisthotonic, and minor absence seizure patterns; major tonic seizures are not well controlled.

This publication has 2 references indexed in Scilit: